ConductScience.org, home

Paper36344331

Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.

Jhajj HS and 3 others. Trends Mol Med, 2023. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Papers, record 36344331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36344331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.
PubMed
Journal
Trends Mol Med
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
2.04
iCite
Revised in PubMed
2024-01-02
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jhajj HSHarkamal S
2Lwo TSTimon S
3Yao ELEmily L
4Tessier PMPeter M

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Humans
Epitopes
Immunotherapy

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R35 GM136300NIGMS NIH HHSUnited StatesR35GM136300PubMed and NIHNIH RePORTER
RF1 AG059723NIA NIH HHSUnited StatesRF1AG059723PubMed and NIHNIH RePORTER

Download CSV of grants

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128405505MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential.Oncoimmunology2017https://conductscience.org/library/papers/28405505PubMed
217709549"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.J Immunol2007https://conductscience.org/library/papers/17709549PubMed
327756788Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.Clin Cancer Res2017https://conductscience.org/library/papers/27756788PubMed
432989604Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.J Cancer Res Clin Oncol2020https://conductscience.org/library/papers/32989604PubMed
533785484An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.Clin Cancer Res2021https://conductscience.org/library/papers/33785484PubMed
624732076OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.Immunol Cell Biol2014https://conductscience.org/library/papers/24732076PubMed
731562320Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.Nat Commun2019https://conductscience.org/library/papers/31562320PubMed
830975201The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.J Immunother Cancer2019https://conductscience.org/library/papers/30975201PubMed
920516446Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol2010https://conductscience.org/library/papers/20516446PubMed
1023744091Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).Protein Eng Des Sel2013https://conductscience.org/library/papers/23744091PubMed
1131573956An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.Clin Cancer Res2019https://conductscience.org/library/papers/31573956PubMed
1224953012Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.Trends Immunol2014https://conductscience.org/library/papers/24953012PubMed
1333148673OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.Clin Cancer Res2021https://conductscience.org/library/papers/33148673PubMed
1427269937Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.J Clin Oncol2016https://conductscience.org/library/papers/27269937PubMed
1527037412RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.Mol Cancer Ther2016https://conductscience.org/library/papers/27037412PubMed
1627856634Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.J Biol Chem2016https://conductscience.org/library/papers/27856634PubMed
1730777098
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Breast Cancer Res2019https://conductscience.org/library/papers/30777098PubMed
1831105267Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.Nat Commun2019https://conductscience.org/library/papers/31105267PubMed
1926008591Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol2015https://conductscience.org/library/papers/26008591PubMed
2023483678Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.Oncoimmunology2013https://conductscience.org/library/papers/23483678PubMed

See all 56 referencesDownload CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42156568Realizing the potential of agonistic antibody immunotherapy.Nat Rev Drug Discov2026https://conductscience.org/library/papers/42156568PubMed
40923270High-voltage electrical pulses for pancreatic cancer treatment in the era of precision medicine.Int J Surg2026https://conductscience.org/library/papers/40923270PubMed
40803893Building a potent TREM2 agonistic, biparatopic, common light chain antibody.MAbs2025https://conductscience.org/library/papers/40803893PubMed
40775487Fifty years of monoclonals: the past, present and future of antibody therapeutics.Nat Rev Immunol2025https://conductscience.org/library/papers/40775487PubMed
40207220Immune inhibitory receptor agonist therapeutics.Front Immunol2025https://conductscience.org/library/papers/40207220PubMed
40004038Pt-Au Nanoparticles in Combination with Near-Infrared-Based Hyperthermia Increase the Temperature and Impact on the Viability and Immune Phenotype of Human Hepatocellular Carcinoma Cells.Int J Mol Sci2025https://conductscience.org/library/papers/40004038PubMed
39582357Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands.MAbs2024https://conductscience.org/library/papers/39582357PubMed
39349829Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.Exp Mol Med2024https://conductscience.org/library/papers/39349829PubMed
39225150Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity.Nanomedicine (Lond)2024https://conductscience.org/library/papers/39225150PubMed
38831760Role of TIM-1 in the development and treatment of tumours.Front Cell Dev Biol2024https://conductscience.org/library/papers/38831760PubMed
38653243Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors.Cell Chem Biol2024https://conductscience.org/library/papers/38653243PubMed
38651411Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.Antibodies (Basel)2024https://conductscience.org/library/papers/38651411PubMed
38429261CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs.Nat Commun2024https://conductscience.org/library/papers/38429261PubMed
38279046Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.Nat Rev Cardiol2024https://conductscience.org/library/papers/38279046PubMed
38168220Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily.bioRxiv2023https://conductscience.org/library/papers/38168220PubMed
38132155Therapeutic Monoclonal Antibodies against Cancer: Present and Future.Cells2023https://conductscience.org/library/papers/38132155PubMed
38102001Harnessing the potential of CD40 agonism in cancer therapy.Cytokine Growth Factor Rev2024https://conductscience.org/library/papers/38102001PubMed
37932534The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity.Cell Mol Immunol2023https://conductscience.org/library/papers/37932534PubMed
37896162Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions.Pharmaceutics2023https://conductscience.org/library/papers/37896162PubMed
37662949Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.Front Immunol2023https://conductscience.org/library/papers/37662949PubMed

See all 22 cited byDownload CSV of cited by

Genes21

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD40958PubTator's text mininghttps://conductscience.org/library/genes/958NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
FAP2191PubTator's text mininghttps://conductscience.org/library/genes/2191NCBI Gene
FCGR2A2212PubTator's text mininghttps://conductscience.org/library/genes/2212NCBI Gene
FCGR2B2213PubTator's text mininghttps://conductscience.org/library/genes/2213NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IGHG33502PubTator's text mininghttps://conductscience.org/library/genes/3502NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
RBFOX3146713PubTator's text mininghttps://conductscience.org/library/genes/146713NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene
TNFRSF10B8795PubTator's text mininghttps://conductscience.org/library/genes/8795NCBI Gene
TNFRSF188784PubTator's text mininghttps://conductscience.org/library/genes/8784NCBI Gene
TNFRSF1A7132PubTator's text mininghttps://conductscience.org/library/genes/7132NCBI Gene
TNFRSF47293PubTator's text mininghttps://conductscience.org/library/genes/7293NCBI Gene

See all 21 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36344331

GET https://conductscience.org/api/papers/v1/36344331/references?page=2